Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor

Bova, Maria;Suffritti, Chiara;Bafunno, Valeria;Loffredo, Stefania;Cordisco, Giorgia;Del Giacco, Stefano;De Pasquale, Tiziana Maria Angela;Firinu, Davide;Margaglione, Maurizio;Montinaro, Vincenzo;Petraroli, Angelica;Radice, Anna;Brussino, Luisa;Zanichelli, Andrea;Zoli, Alessandra;Cicardi, Marco

2020-01-01

---

Abstract

Background Hereditary angioedema (HAE) comprises HAE with C1‐inhibitor deficiency (C1‐INH‐HAE) and HAE with normal C1‐INH activity (nl‐C1‐INH‐HAE), due to mutations in factor XII (FXII‐HAE), plasminogen (PLG‐HAE), angiopoietin 1 (ANGPT1‐HAE), kininogen 1 genes (KNG1‐HAE), or angioedema of unknown origin (U‐HAE). The Italian network for C1‐INH‐HAE (ITACA) created a registry including different forms of angioedema without wheals. Objective We analyzed clinical and laboratory features of a cohort of Italian subjects with nl‐C1‐INH‐HAE followed by ITACA to identify specific biomarkers. Methods A total of 105 nl‐C1‐INH‐HAE patients were studied. Plasma concentrations of cleaved high‐molecular‐weight kininogen (cHK), vascular endothelial growth factors (VEGFs), angiopoietins (Angs), and secreted phospholipase A2 enzymes (sPLA2) were evaluated. Results We identified 43 FXII‐HAE patients, 58 U‐HAE, and 4 ANGPT1‐HAE. We assessed a prevalence of 1:1.4 × 106 for FXII‐HAE and 1:1.0 × 106 for U‐HAE. cHK levels in U‐HAE patients were similar to controls in plasma collected using protease inhibitors cocktail (PIC), but they significantly increased in the absence of PIC. In FXII‐HAE patients, cHK levels, in the absence of PIC, were significantly higher than in controls. We found a significant increase of VEGF‐A, VEGF‐C, and Ang1 levels in U‐HAE patients compared to controls. In FXII‐HAE, only VEGF‐C levels were increased. Ang2 concentrations and sPLA2 activity were not modified. The levels of these mediators in ANGPT1‐HAE patients were not altered. Conclusions Our results suggest that pathogenesis of FXII‐, ANGPT1‐, and U‐HAE moves through an unbalanced control of kallikrein activity, with bradykinin as most likely mediator. VEGFs and Ang1 participate in the pathophysiology of U‐HAE increasing the basal vascular permeability.